Ansamycin: Difference between revisions

64 bytes added ,  1 year ago
Alter: journal, pages. Add: issue. Formatted dashes. | You can use this tool yourself. Report bugs here.
(Alter: journal, pages. Add: issue. Formatted dashes. | You can use this tool yourself. Report bugs here.)
[[File:Geldanamycin.svg|thumb|Structure of [[geldanamycin]], one of the benzoquinone ansamycins.]]
'''Ansamycins''' is a family of bacterial secondary metabolites that show [[antimicrobial]] activity against many [[Gram-positive]] and some [[Gram-negative]] bacteria, and includes various compounds, including [[streptovaricins]] and [[rifamycins]].<ref>{{cite journal |author1=Wehrli, W. |author2=Staehelin, M. |journal=Bacteriol. Rev.Bacteriological Reviews|title=Actions of the rifamycins |volume=35 |issue=3 |pages=290–309 |year=1971 |pmid=5001420 |pmc=378391}}</ref> In addition, these compounds demonstrate antiviral activity towards bacteriophages and [[poxviruses]].
They are named ansamycins (from the Latin '''ansa''', ''handle'') because of their unique structure, which consists of an aromatic moiety bridged by an aliphatic chain.<ref>{{cite journal |author1=Prelog, V. |author2=Oppolzer, W. |journal=Helv. Chim. Acta |title=Rifamycins. 4. Ansamycins, a novel class of microbial metabolism products |volume=56 |pages=2279 |year=1973}}</ref> The main difference between various derivatives of ansamycins is the aromatic moiety, which can be a [[naphthalene]] ring or a [[naphthoquinone]] ring as in [[rifamycin]] and the [[naphthomycin]]s.<ref>{{cite journal |author1=Balerna, M. |author2=Keller-Schierlein, W. |author3=Martius, C. |author4=Wolf, H. |author5=Zähner, H. |journal=Arch. Mikrobiol.Archiv für Mikrobiologie|title=Metabolic products of microorganisms. 72. Naphthomycin, an antimetabolite of vitamin K |volume=65 |pages=303–17 |year=1969 |pmid=4988744 |issue=4 |doi=10.1007/bf00412210}}</ref> Another variation consists of benzene or a benzoquinone ring system as in [[geldanamycin]] or [[ansamitocin]]. Ansamycins were first discovered in 1959 by Sensi et al. from ''[[Amycolatopsis]] mediterranei'', an [[actinomycete]] bacterium.<ref>{{cite journal |author1=Sensi, P. |author2=Margalith, P. |author3=Timbal, M. T. |journal=Ed.Il Sci.Farmaco, Edizione Scientifica|title=Rifomycin, a new antibiotic; preliminary report |volume=14 |issue=2 |pages=146146–7 |year=1959 |pmid=13639988}}</ref>
Rifamycins are a subclass of ansamycins with high potency against mycobacteria. This resulted in their widespread use in the treatment of [[tuberculosis]], [[leprosy]], and AIDS-related mycobacterial infections.<ref>{{cite journal |author1=Floss, H. G. |author2=Yu, T. |journal=Curr. Opin.Current Chem.Opinion Chemical Biology|title=Lessons from the rifamycin biosynthetic gene cluster |volume=3 |pages=592–7 |year=1999 |doi=10.1016/S1367-5931(99)00014-9 |pmid=10508670 |issue=5}}</ref> Since then various analogues have been isolated from other [[prokaryotes]].